注射用单硝酸异山梨酯

中英文简介   瑞阳公司始建于1966年,是一家集研发、生产、销售于一体的现代化制药企业。公司年销售收入70余亿元，综合实力位居中国医药工业企业排行榜前50强。 公司占地面积100万平方米，设有三个厂区，建有粉针（冻干粉针）制剂类、无菌原料药类、固体制剂类和中药制剂类等30多个生产车间，且均通过了中国国家药品GMP认证。年产粉针（含冻干）剂25亿瓶、小容量注射剂3亿支、片剂40亿片、胶囊剂60亿粒、颗粒剂2亿袋、栓剂1000万粒、无菌原料药2000吨。公司还通过了IS09001、ISO14001和OHS18001国际质量、环境、职业健康安全管理体系认证。 多年来，公司坚持以创新驱动发展，先后在北京、上海、苏州、济南以及美国设立了研发中心，主要围绕心脑血管类、呼吸系统、**系统以及抗肿瘤药物等领域，开展新药研发工作。公司在研产品有160多个，其中有52个品种已经上报生产，有18个品种已获得临床批件，有36个品种已上报临床。新产品的陆续上市将进一步增强公司的竞争力。 目前，瑞阳公司的产品已覆盖中国各地，并且在全球60多个国家获得了认可。公司产品出口额6亿元，制剂出口位列中国前五强。随着国际认证步伐的推进，公司产品将逐渐销往欧美等地区，公司的国际化水平将进一步提升。 展望未来，随着新产品陆续上市，瑞阳公司的产品结构将日益完善，生产水平和市场掌控能力将进一步提升，瑞阳公司将会提供一个更广阔的合作平台，与各位朋友携手并进、共谋发展。   Reyoung Pharma was founded in 1966 and has emerged as an integrated modern pharmaceutical enterprise specializing in the R＆D, production and distribution of pharmaceutical products. With an annual sales volume of more than 7 billion RMB, Reyoung was ranked among the top 50 of all the Chinese Pharmaceutical Enterprises.  ` It covers an area of more than 1 million square meters, including 3 factories, and has built 30 workshops including powder for injection workshops (lyophilized), API workshops, solid preparation workshops and traditional Chinese medicine workshops etc. And all of these workshops passed the Chinese national drug GMP certification. The annual output for powder for injections (including lyophilized powder for injections) achieves 2.5 billion vials, small volume injections 300 million ampoules, tablets 4 billion tabs, capsules 6 billion caps, granules 200 million bags, suppository 10 million grains, API 2,000 tons. And Reyoung also passed the IS09001, ISO14001 and OHS18001 international quality, environmental, occupational health and safety management system certification. Reyoung is sticking to the innovation-driven development for many years, and set R&D centers in Beijing, Shanghai, Suzhou, Jinan and USA successively, mainly focuses on the fields of Cardio-cerebrovascular, respiratory system, nervous & mental system, and antineoplastic drugs, to develop and research on that. Now there are more than one hundred and sixty products are under research, and of which more than fifty two has applied for production, and eighteen has got clinical trial permission, and thirty six has been applied for clinical trial. The entering into the market successively of the new products will strengthen the competitiveness of our company. Now the products of Reyoung have covered the whole market of China, and has been successfully approved and marketed in more than 60 countries all over the world. The sales income of export in 2015 is 600 million RMB, and was ranked the top 5 among all the formulation export manufacturers and companies in China. As the promotion of the international certifications, our goods will be marketed to European countries and USA soon, the internationalization level will be improved further. Look into the future, as the entering into the market successively of the new products, the product structure of Reyoung will be improved, the producing levels and the market-controlling power will be enhanced further, and Reyoung will provide a wider platform for our old and new friends to go hand in hand and seek common development.